On this year's cover

On this year's cover

Comment We declare that we have no conflicts of interest. We thank Jennifer Mitty for her helpful comments on an earlier draft. 1 2 3 4 5 6 Gupt...

43KB Sizes 1 Downloads 43 Views

Comment

We declare that we have no conflicts of interest. We thank Jennifer Mitty for her helpful comments on an earlier draft. 1

2

3

4

5

6

Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380: 1250–58. Hamers RL, Schuurman R, Sigaloff KCE, et al, for the PharmAccess African Studies to Evaluate Resistance (PASER) Investigators. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in subSaharan Africa: a multicentre cohort study. Lancet Infect Dis 2012; 12: 307–17. Kasang C, Kalluvya S, Majinge C, et al. HIV drug resistance (HIVDR) in antiretroviral therapy-naive patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high. PLoS One 2011; 6: e23091. Mimiaga, MJ, Smit J, Closson EF, at al. Inkwari: an emerging high-risk venue potentiating HIV spread among adolescents and young adults in a hyperendemic South African setting. 19th International AIDS Conference; Washington, DC, July 22–27, 2012. MOPE151. Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med 2007; 8:171–83. Boscacci RT, Buclin T, Furrer H, Fux CA. A case of voluntary intoxication with efavirenz and lamivudine. AIDS 2006; 20:1352–54.

7

8

9

10

11

12

13

Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med 1999; 159: 2221–24. Larkan F, Van Wyk B, Saris J. Of Remedies and Poisons: Recreational Use of Antiretroviral Drugs in the Social Imagination of South African Carers. Afr Sociol Rev 2010; 14: 62–73. Hull J. Whoonga is the cruelest high. Aljazeera, Oct 22, 2010. http://blogs. aljazeera.net/africa/2010/10/22/whoonga-cruelest-high (accessed Aug 24, 2012). South Africa: no ARVs in ‘whoonga’, say experts. Plusnews, Feb 10, 2011. http://www.plusnews.org/Report/91880/SOUTH-AFRICA-No-ARVs-inwhoonga-say-experts (accessed Aug 24, 2012). Myers B, Siegfried N, Parry CD. Over-the-counter and prescription medicine misuse in Cape Town—findings from specialist treatment centres. S Afr Med J 2003; 93: 367–70. van Heerden MS, Grimsrud AT, Seedat S, Myer L, Williams DR, Stein DJ. Patterns of substance use in South Africa: results from the South African Stress and Health study. S Afr Med J 2009; 99: 358–66. WHO. Lexicon of alcohol and drug terms published by the World Health Organization. http://www.who.int/substance_abuse/terminology/who_ lexicon/en/ (accessed Nov 30, 2012).

On this year’s cover The 2013 cover artist for The Lancet Infectious Diseases is Brett Ryder, who replaces David Mack. We are grateful to David for his popular covers throughout 2012. Brett has previously produced work for many high profile clients: BP, The Observer, NatWest, The Guardian, Penguin Books, NB Studios, BMP, The Independent,

The Times, and New Scientist. We hope you enjoy Brett’s cover for this issue as much as we do. Onisillos Sekkides The Lancet Infectious Diseases, 32 Jamestown Road, London NW1 7BY, UK

Corrections Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12: 290–99. In figure 2, the p values should have been 0·232 in part A, 0·204 in part B, and 0·749 in part C. The corresponding text in paragraph 9 in the Results section should have read “The number of phosphoprotein 65 interferon-γ-producing T cells was increased, although not significantly in a repeated-measurements ANOVA, in the vaccine group compared with the placebo group at all timepoints after transplantation (figure 2).”; and the remainder of the paragraph has been deleted. The corresponding text in the third paragraph of the Discussion section should have read “In our study, vaccine seemed to enhance phosphoprotein 65 cellular immune responses…”. The online version was corrected on Dec 17, 2012. Harding R, Foley KM, Connor SR, Jaramillo E. Palliative and end-of-life care in the global response to multidrug-resistant tuberculosis. Lancet Infectious Diseases 2012; 12: 643–46. In the opening paragraph of the Introduction the definition should have read “Extensively drug-resistant (XDR) tuberculosis is a form of MDR disease that is even more difficult to treat, caused by bacteria that are resistant to at least rifampicin and isoniazid, any fluoroquinolone, and one of three second-line antituberculosis injectable drugs (amikacin, kanamycin, and capreomycin).” The online version was corrected on Dec 17, 2012. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2012; 13: 27. In figure 1, the text in the first box in the last row should have been “8 pharmacokinetic analysis”. The online version was corrected on Dec 17, 2012, the print version is correct.

12

www.thelancet.com/infection Vol 13 January 2013